Article Text

PDF
THU0041 Progranulin and derivatives can be employed as latent dual-function chondrogenic and anti-inflammatory therapeutics for the treatment of rheumatoid arthritis
  1. CMA Schultz,
  2. Y Chernajovsky
  1. Bone & Joint Research Unit, Queen Mary, University of London, London, United Kingdom

Abstract

Background Rheumatoid Arthritis (RA) is a debilitating inflammatory disease of the joints afflicting around 1% of Western populations. Some of the best treatments are anti-TNF agents, but these only achieve remission in 60% of patients and cause deleterious side effects. Progranulin (PGRN), a cysteine-rich, multi-domain growth factor was reported to bind TNF-receptors (TNFR) blocking pro-inflammatory signalling2, as well as stimulating chondrogenesis3. PGRN is cleavable and its peptides have pleiotropic effects, some of which may be beneficial and others refractory to ameliorating RA. Granulin A (GRN A) was shown to interact with cartilage ECM protein COMP4. Atsttrin – comprising 3 fused PGRN regions, was shown to ameliorate arthritic disease2. The latency associated peptide (LAP) of TGFβ1 can be fused to short peptides and cytokines via a MMP cleavage site to facilitate targeting to inflamed sites such as RA joints, reducing side effects and enhancing in vivo half-life1. We hypothesised that a peptide based on PGRN could be fused to LAP and used to both block TNF and stimulate cartilage regeneration in RA joints in a targeted way.

Objectives To produce a panel of PGRN derivatives fused to LAP. To determine the chondrogenic and anti-TNF capacities of the fragments in the presence and absence of MMP activation. To evaluate their efficacy in the CIA model of RA.

Methods Micromass cultures of C28/I2 chondrocytes and C3H10T1/2 mesenchymal cells were employed to determine the ability of PGRN fragments to stimulate chondrogenesis. HT-29 and WEHI-164 TNF sensitive cells were used to evaluate the anti-TNF capacity of LAP-PGRN fragments. Co-immunoprecipitation was used to characterise interactions between PGRN fragments and TNFRII. DBA/1 fibroblasts transduced with lentivirus encoding LAP-PGRN fusions were delivered to DBA/1 mice with CIA to assess anti-arthritic effects.

Results PGRN, LAP-PGRN, LAP-GRN A and LAP-Atsttrin were cloned and expressed in mammalian expression systems. PGRN elevated sulphated proteoglycan production in micromass cultures of C28/I2 human chondrocytes, and also stimulated proliferation of C3H10T1/2 cells. Furthermore, PGRN reduced TNF-mediated catabolism of extracellular matrix in established chondrogenic C3H10T1/2 micromass cultures. LAP-PGRN, LAP-GRN A and LAP-Atsttrin potentiated BMP2 mediated chondrogenesis in C3H10T1/2 micromasses. PGRN failed to protect WEHI-164 fibroblasts or HT-29 colorectal carcinoma cells from TNF-mediated cytotoxicity despite interacting with TNF receptor in vitro by co-immunoprecipitation. LAP-PGRN, LAP-GRN A and LAP-Atsttrin all failed to protect WEHI-164 cells from TNF-mediated cytotoxicity, even after MMP1 cleavage and release. CIA disease progression was reduced in DBA/1 mice treated with autologous fibroblasts overexpressing murine Etanercept or PGRN relative to control treatment. LAP-Atsttrin was more effective than LAP-PGRN and LAP-GRN A at reducing arthritic symptoms relative to LAP-Empty controls.

Conclusions These findings suggest that PGRN could be used as a targeted dual-function chondrogenic and anti-inflammatory treatment for RA, but these effects are not elicited directly through the TNF pathway.

References

  1. Adams et al., Nat Biotechnol. 2003 Nov;21(11):1314–20.

  2. Tang et al., Science. 2011 Apr 22;332(6028):478–84.

  3. Feng et al., FASEB J. 2010 Jun;24(6):1879–92.

  4. Xu et al., J Biol Chem. 2007 Apr 13;282(15):11347–55.

References

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.